DIDREX (benzphetamine hydrochloride) by Pfizer is clinical pharmacology benzphetamine hydrochloride is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, the amphetamines. Approved for the management of exogenous obesity, higher. First approved in 1960.
Drug data last refreshed 7h ago · AI intelligence enriched 6d ago
DIDREX (benzphetamine hydrochloride) is a sympathomimetic amine oral tablet approved in 1960 for management of exogenous obesity. It works through central nervous system stimulation and blood pressure elevation to suppress appetite, though the exact mechanism beyond appetite suppression remains unclear. Clinical studies show modest weight loss benefit (a fraction of a pound per week above placebo) with tolerance developing over time.
Product approaching loss of exclusivity with minimal remaining commercial potential; career opportunities shrinking as team consolidates toward lifecycle management.
CLINICAL PHARMACOLOGY Benzphetamine hydrochloride is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance…
Worked on DIDREX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Zero linked job openings reflect DIDREX's status as a legacy maintenance brand with minimal staffing needs. Career opportunities are scarce and primarily focused on regulatory defense, cost management, and ensuring brand continuity rather than growth, innovation, or market expansion. This is a stabilization-phase role suitable only for professionals seeking low-intensity legacy portfolio management.